The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Abstract
Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab, trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with HER2-positive metastatic breast cancer. In the primary analysis and subsequent reports, progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group. Here, we report the end-of-study analysis of CLEOPATRA.Methods This was a double-blind, randomised, placebo-controlled, phase 3 trial that was done at 204 centres in 25 countries. Eligible patients were 18 years or older, had HER2-positive, metastatic breast cancer, had not received previous chemotherapy or biological treatment for their metastatic disease, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. All study drugs were given intravenously, every 3 weeks. Patients were assigned to receive either pertuzumab or placebo at a loading dose of 840 mg, and 420 mg thereafter; plus trastuzumab at 8 mg/kg loading dose and 6 mg/kg thereafter; and docetaxel at 75 mg/m 2, escalating to 100 mg/m 2 if tolerated. Pertuzumab or placebo and trastuzumab were given until disease progression; docetaxel was given for six cycles, or longer at the investigators' discretion. Randomisation (1:1) was done by use of an interactive voice-response system and was stratified by geographical region (Asia, Europe, North America, or South America) and previous treatment (previous adjuvant or neoadjuvant chemotherapy vs none). The primary endpoint was independent review facility-assessed progression-free survival, which has been reported previously. Since the confirmatory overall survival analysis had also occurred before this prespecified end-of-study analysis, analyses presented here are descriptive. Overall survival analyses were based on the intention-to-treat population with crossover patients analysed in the placebo group; analyses were not adjusted for crossover to the pertuzumab group and are likely to be conservative. Safety analyses were based on treatment received; crossover patients were counted in the placebo group up to the day before first pertuzumab dose. This trial is registered with ClinicalTrials.gov, number NCT00567190.Findings Between Feb 12, 2008, and July 7, 2010, 1196 patients were assessed for eligibility, of whom 808 were enrolled and randomly assigned. 402 patients were assigned to receive docetaxel plus trastuzumab plus pertuzumab, and 406 patients were assigned to receive docetaxel plus trastuzumab plus placebo. Clinical cutoff for this analysis was Nov 23, 2018. Between July 2012 and clinical cutoff, 50 patients crossed from the placebo to the pertuzumab group. Median follow-up was 99·9 months in the pertuzumab group (IQR 92·9-106·4) and 98·7 months (90·9-105·7) in the placebo group. Median overall survival was 57·1 months (95% CI 50-72) in the pertuzumab group and 40·8 months (36-48) in the placebo group (hazard ratio 0·69, 95% CI 0·58-0·82); 8-year landmark overall survival rates were 37% (95% CI 31-42) in the pertuzumab group and 23% (19-28) in the placebo group. The most common grade 3-4 adverse event was neutropenia (200 [49%] of 408 patients in the pertuzumab group, 183 [46%] of 396 patients in the placebo group). Five (1%) of 408 patients in the pertuzumab group and six (2%) of 396 patients in the placebo group had treatment-related deaths. One new serious adverse event suggestive of congestive heart failure (pertuzumab group) and one new symptomatic left ventricular systolic dysfunction (post-crossover) occurred since the previous analysis.Interpretation Our analysis shows that the previously observed improvements in overall survival with pertuzumab, trastuzumab, and docetaxel versus placebo, trastuzumab, and docetaxel were maintained after a median of more than 8 years of follow-up. The long-term safety and cardiac safety profiles of pertuzumab, trastuzumab, and docetaxel were maintained in the overall safety population and within crossover patients. HER2-targeted therapy has changed the natural history of HER2-positive metastatic breast cancer, with the dual blockade of pertuzumab and trastuzumab, with docetaxel, demonstrating an 8-year landmark overall survival rate of 37%.Funding F Hoffmann-La Roche and Genentech.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [21]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationTrastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationAdjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Self-citationSchneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Self-citationRoss, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citation
Cited by
Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., Gligorov, J., Hurvitz, S. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.019 · Cited by 1,417
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333
Targeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160
Self-citationNCCN Guidelines® Insights: Breast Cancer, Version 4.2023: Featured Updates to the NCCN Guidelines
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0031 · Cited by 453
Breast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
“The recommended first-line therapy is currently dual HER2 blockade with trastuzumab and pertuzumab in combination with chemotherapy (preferably taxanes) [204, 205].”
Background
Metadata
- Authors
- Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., Clark, E., Knott, A., Restuccia, E., Benyunes, M. C., Cortés, J., Agajanian, R., Ahmad, R., Aktas, B., Alencar, V. H., Amadori, D., Andrade, J., André Franke, F., Angiolini, C., Aogi, K., Armor, J., Arpornwirat, W., Assersohn, L., Audeh, W., Aulitzky, W., Azevedo, S., Bartoli, M. A., Batista Lopez, N., Bianconi, M., Biganzoli, L., Birhiray, R., Bitina, M., Blachy, R., Blackwell, K., Blanchard, R., Blanchet, P., Boiangiu, I., Bower, B., Brezden-Masley, C., Brufsky, A., Budde, L., Caguioa, P., Calvo, L., Campone, M., Carroll, R. R., Castro, H., Chan, V., Charu, V., Cinieri, S., Clemens, M., Conejo, E. A., Côrtes, E., Coudert, B., Cronemberger, E., Cubero, D., Dakhil, S., Daniel, B., Davidson, N., De Fatima Gaui, M., De La Cruz, S., Del Pilar, M., Delgado, G., Ellerton, J. A., Estuardo, C., Fehrenbacher, L., Ferrero, J.-M., Flynn, P. J., Foszczynska-Kloda, M., Franco, S., Fujii, H., Gallagher, C., Gamucci, T., Giacomi, N., Gil I Gil, M., Gonzalez Martin, A., Gorbunova, V., Gotovkin, E., Green, N., Grincuka, E., Grischke, E.-M., Hansen, V., Hargis, J., Hauschild, M., Hegg, R., Hendricks, C., Hermann, R., Hoff, P., Horiguchi, J., Hornedo Muguiro, J., Iacobelli, S., Inoue, K., Ismael, G., Itoh, Y., Iwata, D. H., Jendiroba, D., Jochim, R., Jones, A., Just, M., Kallab, A., Karwal, M., Kashiwaba, M., Kato, G., Kaufman, P. A., Kellokumpu-Lehtinen, P., Kirsch, A., Kiselev, I., Klein, P., Kohno, N., Kopp, M., Kostovska-Maneva, L., Kotliar, M., Kudaba, I., Kümmel, S., Kuroi, K., Lacava, J., Latini, L., Lee, S. C., Lichinitser, M., Lobo, C., Maintz, C., Maneecahvakajorn, J., Marmé, A., Martinez, G., Masuda, N., Matwiejuk, M., Merculov, V., Michaelson, R., Miguel, L., Monroy, H., Montemurro, F., Morales, S., Moura, R., Mueller, V., Mulatero, C., Nakagami, K., Nakayama, T., Neidhart, J., Nguyen, A., Nishimura, R., Ogata, H., O'reilly, S., O'rourke, T., Otero Reye, D., Ouyang, X., Patel, R., Patel, T., Pedrini, J. L., Pereira, R., Perez, A., Peterson, C., Pienkowski, T., Pinczowski, H., Polikoff, J., Polkowski, W., Price, P. E., Prill, S., Priou, F., Purkalne, G., Pyrhoenen, S., Quackenbush, R., Rai, Y., Ribelles, N., Ro, J., Robinson, A., Robles, R., Rodriguez, G., Roman, L., Saji, S., Sanchez-Rovira, P., Sato, N., Schmidt, M., Schumacher, C., Senecal, F., Sharma, P., Shen, Z., Shirinkin, V., Simoncini, E., Sirisinha, T., Smith, R., Sohn, J.-H., Soldic, Z., Soria, T., Spicer, D., Srimuninnimit, V., Sriuranpong, V., Staroslawska, E., Stefanovski, P., Sunpaweravong, P., Taguchi, J., Takeda, K., Tellez-Trevilla, G., Thomas, R., Thomssen, C., Toache, Z., Tokuda, Y., Tomczak, P., Tosello, C., Tsugawa, K., Tudtud, D., Ueno, T., Van Eyll, B., Varela, M., Vasev, N., Vrbanec, D., Wang, X., Wang, L., Watanabe, J., Waterhouse, D., Wesenberg, B., Wheatley, D., Wong, Z. W., Yadav, S., Yadav, S., Yardley, D., Yau, T.-K., Yeo, W., Ying, C., & Youn Oh, D.
- Affiliations
- Georgetown University Medical Center (US)
- Mount Vernon Hospital (GB)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University (KR)
- Hospital Universitario 12 De Octubre (ES)
- German Cancer Research Center (DE)
- Peter MacCallum Cancer Centre (AU)
- F. Hoffmann-La Roche AG (CH)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Institute of Oncology (ES)
- Institute of Oncology NN Petrov (RU)
- Corresponding author
- Swain, Sandra M
- ORCID
- Swain, Sandra M
- Miles, David
- Kim, Sung-Bae
- Im, Young-Hyuck
- Im, Seock-Ah
- Ciruelos, Eva
- Schneeweiss, Andreas
- Loi, Sherene
- Clark, Emma
- Restuccia, Eleonora
- Cortés, Javier
- Aktas, Bahriye
- Andrade, Jurandyr
- Angiolini, Catia
- Aogi, Kenjiro
- Audeh, William
- Bianconi, María
- Biganzoli, Laura
- Birhiray, Ruemu
- Blackwell, Kimberly
- Brufsky, Adam
- Caguioa, Priscilla
- Calvo, Lourdes
- Campone, Mario
- Cinieri, Saverio
- Coudert, Bruno
- Cronemberger, Eduardo
- Cubero, Daniel
- Dakhil, Shaker
- Delgado, Gilson
- Ellerton, John A.
- Fehrenbacher, Louis
- Ferrero, Jean-Marc
- Flynn, Patrick J.
- Fujii, Hirofumi
- Gorbunova, Vera
- Grischke, Eva-Maria
- Hegg, Roberto
- Hoff, Paulo
- Horiguchi, Jun
- Inoue, Kenichi
- Ismael, Gustavo
- Itoh, Yoshinori
- Jones, Alison
- Just, Marianne
- Karwal, Mark
- Kashiwaba, Masahiro
- Kaufman, Peter A.
- Klein, Paula
- Kohno, Norio
- Lee, Soo Chin
- Masuda, Norikazu
- Montemurro, Filippo
- Morales, Serafin
- Nakayama, Takahiro
- Nishimura, Reiki
- Patel, Ravi
- Polkowski, Wojciech
- Priou, Frank
- Ribelles, Nuria
- Ro, Jungsil
- Robinson, Anne
- Rodriguez, Gladys
- Saji, Shigehira
- Sato, Nobuaki
- Schmidt, Marcus
- Schumacher, Claudia
- Sharma, Priyanka
- Shen, Zhenzhou
- Shirinkin, Vadim
- Simoncini, Edda
- Sriuranpong, Virote
- Sunpaweravong, Patrapim
- Thomssen, Christoph
- Tokuda, Yutaka
- Tomczak, Piotr
- Ueno, Takayuki
- Wang, Xiaojia
- Wang, Liwei
- Watanabe, Junichiro
- Waterhouse, David
- Wheatley, Duncan
- Wong, Zee Wan
- Yardley, Denise
- Yeo, Winnie
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 519-530
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W3012380787
- Cited by
- 922
- References
- 31
- Citations by year
- 2026: 115 · 2025: 164 · 2024: 175 · 2023: 182 · 2022: 132 · 2021: 114 · 2020: 40
- FWCI
- 42.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Genentech
- F. Hoffmann-La Roche
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, progression-free survival, overall survival, CLEOPATRA trial, HER2-targeted therapy, treatment safety, adverse events, cardiotoxicity, neutropenia, thrombocytopenia, hyperbilirubinemia
- MeSH terms
- Trastuzumab, Docetaxel, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Metastasis, Survival Analysis, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30863-0
- The paper
- Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., Clark, E., Knott, A., Restuccia, E., Benyunes, M. C., Cortés, J., Agajanian, R., Ahmad, R., Aktas, B., Alencar, V. H., . . . Youn Oh, D. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30863-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.